Europe In-vitro Diagnostics Market to Grow at a CAGR of 4.2% During the Period 2024-2032, Driven by Need for Effective and Efficient Detection Technologies

In-vitro diagnostics (IVD) refer to tests carried out on samples such as blood or tissue taken from the human body. In vitro diagnostics can detect diseases, infections, or other conditions, and may be used to monitor a person’s overall health to help treat, cure, or prevent illnesses.

Leading companies are engaged in developing solutions enabling efficient and accurate detection of illnesses. For example, in 2021, QIAGEN and INOVIO Pharmaceuticals announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO's therapies. Such developments are expected to drive the Europe in-vitro diagnostics market. The initial project in the expanded collaboration focused on the co-development of a diagnostic test that identified women who were most likely to benefit from clinical use of VGX-3100, INOVIO's immunotherapy to treat advanced cervical dysplasia associated with the human papillomavirus (HPV). QIAGEN's bioinformatic expertise would further increase the predictive power of INOVIO's preliminary biomarker signature – and the assay would be developed for use on the Illumina NextSeq™ 550Dx platform, the first development based on a partnership QIAGEN and Illumina signed in October 2019.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

In 2019, QIAGEN and Illumina joined forces in the next-gen sequencing-based IVD testing and companion diagnostics market announcing a 15-year collaboration. For Illumina, the collaboration with Qiagen was set to add long-term expansion potential, specifically in the expanding market for companion diagnostics for targeted cancer therapies and immuno-oncology.

In 2022, bioMérieux announced that it had finalized the acquisition of Specific Diagnostics, a privately held U.S. based company that had developed a rapid antimicrobial susceptibility test (AST) system that delivered phenotypic AST directly from positive blood cultures. With the acquisition, bioMérieux sought to further develop its global leadership in clinical microbiology, bringing major innovation to the market and strengthen its fight against antimicrobial resistance.

In 2019, Siemens Healthineers (Erlangen, Germany) showcased its broad portfolio of products and services in its core areas of laboratory diagnostics and molecular medicine at MedLab Middle East 2019. MedLab was the only medical laboratory industry event that offered producers the chance to meet a variety of buyers. At MedLab Middle East 2019, Siemens highlighted its Atellica Solution series of flexible, scalable, automation-ready immunoassay and chemistry analyzers. Such solutions are expected to drive the Europe in-vitro diagnostics markets. The company demonstrated how the Atellica Solution delivered even more control and simplicity for labs with revolutionary sample-management possibilities.

In 2021, European Commission proposed a progressive roll-out of the new In Vitro Diagnostic Medical Devices Regulation to avoid disruption in the supply of these essential healthcare products. Such developments are likely to boost market growth.

Key Findings of the Report:

• The Europe in-vitro diagnostics market is expected to be driven by the need for effective and efficient detection technologies.

• Advanced solutions are expected to boost market growth.

• New regulations are likely to stimulate market growth.

Market Analysis by Product and Services, Technology, Application, End Use, and Country:

• By product and services, the market is segmented into Reagents and Kits, Instruments, and Software and Services.

• By technology, the market is classified into Immunoassay/Immunochemistry, Clinical Chemistry, Molecular Diagnostics, Haematology, Microbiology, Blood Glucose Self-monitoring, Coagulation and Haemostasis, Urinalysis, and Others.

• By application, the market is divided into Infectious Diseases, Diabetes, Cardiology, Oncology, Autoimmune Diseases, Nephrology, and Others.

• By end use, the market is segmented into Hospitals, Laboratories, Homecare, and Others.

• By country, the market is divided into United Kingdom, Germany, France, Italy, and Others.

About Us

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us

Expert Market Research
Website: www.expertmarketresearch.com
Email: [email protected]
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790